As of June 30, 2025, CervoMed (CRVO) had approximately $33.5 million in cash, cash equivalents and marketable securities, as compared to $38.9 million as of December 31, 2024. Based on its current operating plan, CervoMed believes its cash, cash equivalents and marketable securities on hand as of June 30, 2025, along with remaining funds to be received from the Company’s grant from the NIA, will enable the Company to fund its planned operating expenses and capital expenditure requirements into the third quarter of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Shares Business and Financial Updates Online
- CervoMed price target raised to $27 from $21 at Canaccord
- CervoMed’s Promising Clinical Trial Data and Strategic Focus Boost Buy Rating and Price Target
- CervoMed Announces Positive Phase 2b Trial Results
- CervoMed announces 32-week data from Extension phase of Phase 2b RewinD-LB